April Greene Colozzi
About April Greene Colozzi
April Greene Colozzi is a scientist at Accent Therapeutics, Inc. in Lexington, Massachusetts, with over ten years of experience in translational oncology and biotechnology development.
Work at Accent Therapeutics
April Greene Colozzi has been employed as a Scientist at Accent Therapeutics, Inc. since 2019. In this role, she has contributed to the company's research initiatives in Lexington, Massachusetts. Prior to her current position, she served as a Principal Research Associate at the same organization for 11 months. Her ongoing work focuses on advancing the understanding and development of biotechnologies within the field of oncology.
Education and Expertise
April Greene Colozzi holds a Master's degree in Biotechnology and Liberal Arts from Harvard University, where she studied from 2013 to 2016. She also earned a Bachelor of Arts in Biology from Wheaton College, completing her studies from 2005 to 2009. Her educational background supports her expertise in developing new biotechnologies and applications in preventive medicine, particularly in the context of translational oncology.
Background
April Greene Colozzi has over ten years of experience in the fields of translational oncology and platform development. Her career spans both industry and academia, providing her with a diverse skill set. She began her professional journey as a Research Assistant and Lab Manager at Wheaton College, followed by significant roles at Dana-Farber Cancer Institute, Ariad Pharmaceuticals, and Intellia Therapeutics before joining Accent Therapeutics.
Previous Positions
Before her current role at Accent Therapeutics, April Greene Colozzi held several significant positions. She worked as a Lead Research Technician and Lab Manager at Dana-Farber Cancer Institute from 2009 to 2015. She then transitioned to Ariad Pharmaceuticals as a Senior Associate Scientist from 2015 to 2017, and subsequently joined Intellia Therapeutics in the same capacity until 2019. These roles have contributed to her extensive experience in the biotechnology sector.